Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Monique A Hartley-Brown"'
Autor:
Monique A Hartley-Brown, Lubomir Sokol, Gisela L Caceres, Mohammed A Hussein, Alan List, Javier Pinilla-Ibarz
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 2, Iss 1, Pp e2010002-e2010002 (2010)
A 60-year-old woman with a medical history of diabetes mellitus, osteoporosis, peripheral vascular disease, and hypertension who was otherwise asymptomatic but continued showing elevated neutrophil levels sought a second opinion at our facility. Seru
Externí odkaz:
https://doaj.org/article/a58b0ea1d62c43a68cfe687199a7676c
Autor:
Clifton C. Mo, Andrew J. Yee, Shonali Midha, Monique A. Hartley‐Brown, Omar Nadeem, Elizabeth K. O'Donnell, Giada Bianchi, Adam S. Sperling, Jacob P. Laubach, Paul G. Richardson
Publikováno v:
eJHaem, Vol 4, Iss 3, Pp 792-810 (2023)
Abstract Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nu
Externí odkaz:
https://doaj.org/article/df6d5d22d8aa4c3088dccaac48019fd0
Autor:
Tondre Buck, Monique A. Hartley-Brown, Yvonne A. Efebera, Carter P. Milner, Jeffrey A. Zonder, Paul G. Richardson, Taylor Salinardi, Megan S. Rice
Publikováno v:
Haematologica, Vol 109, Iss 6 (2023)
Examination of the impact of race and ethnicity on multiple myeloma (MM) outcomes has yielded inconsistent results. This retrospective, real-world (RW) study describes patient, disease, and treatment characteristics (and associations with survival ou
Externí odkaz:
https://doaj.org/article/4f1f9c13d5ba430dba88d9086aeb624c
Publikováno v:
The Cancer Journal. 27:222-230
In the past several years, there have been significant advances in the therapeutic arsenal of agents used to treat multiple myeloma (MM). Despite these advances, MM remains incurable. One of the most recent therapeutic advances is the development of
Autor:
David W Chitty, Kenar D. Jhaveri, Vinay Nair, Monique A. Hartley-Brown, Rimda Wanchoo, Richa Thakur, Mersema Abate
Publikováno v:
Nephrology Dialysis Transplantation. 37:1616-1626
There have been significant advances in the treatment of multiple myeloma in the last 2 decades. Approximately 25% of patients with newly diagnosed myeloma have some degree of kidney impairment. During the course of illness, nearly 50% of myeloma pat
Publikováno v:
Blood. 136:1-2
Background: Survival outcomes of Multiple Myeloma (MM) patients have significantly increased with recent advances in treatment. In the past decade several agents have been FDA approved due to improvement in the progression-free survival (PFS). Kyprol
Publikováno v:
Advances in Malignant Hematology
Autor:
Y. Ann Chen, Mohamad A. Hussein, Brianna Perez, Kaaron Benson, Richard Z. Liu, Jamie K. Teer, Elizabeth R. Remily-Wood, Sean J. Yoder, Rachid Baz, John M. Koomen, Monique A. Hartley-Brown, Steven A. Eschrich, Robert Sprung
Publikováno v:
Proteomics. Clinical applications. 8(9-10)
Quantitative MS assays for Igs are compared with existing clinical methods in samples from patients with plasma cell dyscrasias, for example, multiple myeloma (MM).Using LC-MS/MS data, Ig constant region peptides, and transitions were selected for LC
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 4, Iss , Pp 100094- (2021)
Plasma cell neoplasms (PCNs) in post solid organ transplant is a rare occurrence. To date, there is no standardized protocol for treatment. Management is further complicated in World Trade Center (WTC) survivors who present with post- solid organ tra
Externí odkaz:
https://doaj.org/article/d20afac23e84422298c62f4ad6a0bed6
Publikováno v:
Advances in Hematology, Vol 2010 (2010)
Multiple myeloma is an incurable disease, although patient survival has increased with the availability of novel agents. Both multiple myeloma and its therapies often affect the renal, immune, skeletal, hematologic, and nervous systems. The resulting
Externí odkaz:
https://doaj.org/article/079c15e81cfa4218a90b17f08566fb79